Fig. 2From: Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trialPFS according to the number of CTCs at T1 timepoint. 2: a CTCs categorized by 1 or more CTCs and = 0 CTCs cut off; b categorized by < 5 and ≥ 5 CTCs cut offBack to article page